APD588, a Novel, Selective S1P Receptor Modulator, Inhibits Inflammation and Airway Hyperresponsiveness in the Ovalbumin-induced Model of Allergic Asthma

Catherine M. Crosby,1 H. Kiyomi Komori,1 Ronald Christopher2, John W. Adams1

1Arena Pharmaceuticals; 2Parallel 33 Consulting

**ABSTRACT**

- **Background:** FTY720 is a non-selective sphingosine 1-phosphate (S1P) receptor modulator that has shown efficacy in preclinical models of asthma. APD588 is a next-generation S1P receptor modulator with increased selectivity and potential for an improved safety profile. We hypothesized that the optimized S1P receptor profile of APD588 would confer beneficial effects in an ovalbumin (OVA)-induced asthma model.

- **Aim:** To evaluate efficacy of prophylactic APD588 in the OVA-induced allergic asthma model.

- **Methods:** Receptor potency and selectivity profile of APD588 was determined (β-arestin, GTPyS) in cell lines expressing recombinant human S1P receptors (S1P1-15). Efficacy in allergic asthma was assessed in BALB/c mice which were sensitized with intraperitoneal OVA on days 0, 7, and 17, then exposed to intratracheal (IT) vehicle or OVA on days 21-23. From day 20, vehicle, APD588 or FTY720 were administered IT, QD. On day 24, airway hyperresponsiveness (AHR), immune cell infiltration and cytokine expression in BAL were measured.

- **Results:** APD588 was a potent modulator of S1P1, with less potency at S1P3, and no detectable activity at S1P2, 4, 5. IT treatment of APD588 produced a dose-dependent inhibition of methacholine-induced AHR, significantly inhibited airway eosinophil and lymphocyte infiltration, and inhibited BAL cytokines IL-4 and IL-5. FTY720 also reduced antigen-induced AHR and neutrophil and lymphocyte BAL cell counts, but had no significant effect on eosinophil counts or Th2 cytokines.

- **Conclusions:** APD588 was an effective IT therapy for OVA-induced asthma. Lung function improvements correlated with reduced Th2 cytokines and lymphocyte and eosinophil infiltration in the BAL. Based on these results, APD588 may have therapeutic potential in asthma, and broadly indicate potential in other atopic Th2-mediated diseases.

**METHODS**

**Figure 1: 588 Receptor Pharmacology**

- APD588 is a potent modulator of S1P1, while FTY720 is a non-specific S1P receptor modulator. Receptor potency and selectivity profile of APD588 and FTY720 were determined in cell lines expressing recombinant human S1P receptors (S1P1-15). For each assay, values below indicate EC50, % efficacy of agonism (number of replicates).

<table>
<thead>
<tr>
<th>Receptor</th>
<th>APD588</th>
<th>FTY720</th>
</tr>
</thead>
<tbody>
<tr>
<td>S1P1</td>
<td>0.64 nM</td>
<td>116% (36)</td>
</tr>
<tr>
<td>S1P2</td>
<td>&gt;10,000 nM</td>
<td>100% (3)</td>
</tr>
<tr>
<td>S1P3</td>
<td>123 nM</td>
<td>100% (3)</td>
</tr>
<tr>
<td>S1P4</td>
<td>2.95 nM</td>
<td>100% (3)</td>
</tr>
<tr>
<td>S1P5</td>
<td>&gt;10,000 nM</td>
<td>100% (3)</td>
</tr>
</tbody>
</table>

**Figure 2: Experimental Design**

- Female BALB/c mice sensitized, treated, and challenged according to the schematic below. APD588 doses based on previous studies and potency. The 12.5 µg/kg dose for the comparator FTY720 was chosen based on previously published reports in this model.

**Figure 3: APD588 Reduces Lung Lymphocytes and Eosinophils**

- Upon Ova challenge, IT-administered APD588 reduced the infiltration of (A) lymphocytes and (B) eosinophils in the BAL in a dose-dependent manner.

**Figure 4: APD588 Reduces Th2 Cytokines in BAL**

- APD588 reduced the concentration of (A) IL-4 and (B) IL-5 in the BAL in a dose-dependent manner.

**RESULTS**

**Figure 5: APD588 Inhibits Methacholine-induced Airway Hyperresponsiveness**

APD588 inhibited airway responsiveness to methacholine (Mch), as measured by a reduction in (A, B) airway resistance and (C, D) airway compliance.

<table>
<thead>
<tr>
<th>Vehicle/Saline</th>
<th>Vehicle/Ova</th>
<th>APD588 (112.5 µg/kg)/Ova</th>
<th>FTY720 (12.5 µg/kg)/Ova</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Resistance</td>
<td>Actual Values Measured</td>
<td>Resistance % Change from Baseline</td>
<td></td>
</tr>
<tr>
<td>Mch (mg/kg i.v.)</td>
<td>Mch (mg/kg i.v.)</td>
<td>Mch (mg/kg i.v.)</td>
<td></td>
</tr>
</tbody>
</table>

**CONCLUSIONS**

- An aerosolized challenge of ovalbumin to the vehicle treated animals resulted in a significant increase in methacholine-induced airway hyperresponsiveness, increase in total and differential cell counts in the BAL fluid when compared to the vehicle treated saline challenged animals. Antigen challenge also induced increases in BAL pro-inflammatory cytokines, IL-4 and IL-5.

- In antigen challenged, sensitized mice, APD588 at 112.5 µg/kg significantly inhibited methacholine-induced airway hyperresponsiveness and significantly decreased eosinophil and lymphocyte counts. APD588 at 112.5 µg/kg also induced a statistically significant decrease in IL-4 and IL-5. APD588 dosed at 112.5 µg/kg also produced a significant reduction in the severity of the lung-induced tissue inflammatory response and mucous cell hyperplasia. APD588, when dosed at 37.5 µg/kg, produced a significant decrease in lymphocyte count, IL-4 and IL-5 in the BAL fluid. It also produced a significant reduction in the severity of the lung-induced inflammatory response in the tissue and mucous cell hyperplasia. FTY720 and APD588 dosed at the lowest concentration (12.5 µg/kg) did not show any statistically significant or noteworthy effects.

- In conclusion, APD588 was an effective IT therapy for OVA-induced asthma. Lung function improvements correlated with reduced Th2 cytokines and lymphocyte and eosinophil infiltration in the BAL. Notably, reductions in IL-5 correlated with reduced eosinophil recruitment. Based on these results, APD588 may have therapeutic potential in allergic and eosinophilic asthma subtypes, and broadly indicate potential in other atopic Th2-mediated diseases.

**REFERENCES**


**ACKNOWLEDGMENTS**

These studies were supported by Arena Pharmaceuticals, Inc. (San Diego, CA), Sappho Communications, Inc. (Woodland Hills, CA) provided medical writing support funded by Arena Pharmaceuticals, Inc.

**DISCLOSURES**

CC, KK, and JA are employees of Arena Pharmaceuticals, Inc.